These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29719482)

  • 1. First Results and Experience with PRRT in South Africa.
    Vorster M; Modiselle MR; Corbett CS; Lawal IO; Buscombe JR; Sathekge MM
    World J Nucl Med; 2018; 17(2):86-93. PubMed ID: 29719482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of hitherto unknown brain meningioma detected on
    Parghane RV; Talole S; Basu S
    World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant
    Ballal S; Yadav MP; Tripathi M; Sahoo RK; Bal C
    J Nucl Med; 2022 Jul; ():. PubMed ID: 35863893
    [No Abstract]   [Full Text] [Related]  

  • 4. Initial clinical evaluation of indigenous
    Parghane RV; Mitra A; Bannore TU; Rakshit S; Banerjee S; Basu S
    World J Nucl Med; 2021; 20(1):73-81. PubMed ID: 33850492
    [No Abstract]   [Full Text] [Related]  

  • 5. Peptide Receptor Radionuclide Therapy Using
    Kalantarhormozi M; Hassanzadeh S; Rekabpour SJ; Ravanbod MR; Jafari E; Amini A; Dadgar H; Mahmoudpour M; Nabipour I; Jokar N; Assadi M
    World J Nucl Med; 2022 Sep; 21(3):215-221. PubMed ID: 36060085
    [No Abstract]   [Full Text] [Related]  

  • 6. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Thapa P; Parghane R; Basu S
    World J Nucl Med; 2017; 16(3):223-228. PubMed ID: 28670182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE.
    Basu S; Ranade R; Thapa P
    World J Nucl Med; 2016; 15(1):38-43. PubMed ID: 26912977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage PRRT with
    Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
    BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Safety and Efficacy of the Repeated PRRT with [
    Zemczak A; Gut P; Pawlak D; Kołodziej M; Królicki L; Kos-Kudła B; Ruchała M; Kamiński G; Kunikowska J
    Int J Endocrinol; 2021; 2021():6615511. PubMed ID: 33552155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Survival and Value of
    Rodrigues M; Winkler KK; Svirydenka H; Nilica B; Uprimny C; Virgolini I
    Life (Basel); 2021 Mar; 11(3):. PubMed ID: 33806393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
    Haug AR; Auernhammer CJ; Wängler B; Schmidt GP; Uebleis C; Göke B; Cumming P; Bartenstein P; Tiling R; Hacker M
    J Nucl Med; 2010 Sep; 51(9):1349-56. PubMed ID: 20720050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of
    Lee H; Kipnis ST; Niman R; O'Brien SR; Eads JR; Katona BW; Pryma DA
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of baseline Ga-68 DOTATATE positron emission tomography/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with Lu-177 DOTATATE.
    Soydal Ç; Peker A; Özkan E; Küçük ÖN; Kir MK
    Turk J Med Sci; 2016 Feb; 46(2):409-13. PubMed ID: 27511504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term prognostic factors for PRRT in neuroendocrine tumors.
    Trautwein NF; Schwenck J; Jacoby J; Reischl G; Fiz F; Zender L; Dittmann H; Hinterleitner M; la Fougère C
    Front Med (Lausanne); 2023; 10():1169970. PubMed ID: 37359009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of receptor radionuclide therapy with
    Nicolini S; Severi S; Ianniello A; Sansovini M; Ambrosetti A; Bongiovanni A; Scarpi E; Di Mauro F; Rossi A; Matteucci F; Paganelli G
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):923-930. PubMed ID: 29387927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response.
    Vaughan E; Machta J; Walker M; Toumpanakis C; Caplin M; Navalkissoor S
    Br J Radiol; 2018 Nov; 91(1091):20180041. PubMed ID: 29513039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT.
    Zwirtz K; Hardt J; Acker G; Baur ADJ; Pavel M; Huang K; Brenner W; Prasad V
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745849
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.